Biosecurity laws hobble research

Ever since the U.S. government has taken steps to protect and encourage research involving pathogens that could be used as biological weapons, that research has become much less efficient, according to a new analysis.

Image: Wikimedia Commons

Though funding for research on so-called "select agents," or pathogens that can be used as weapons, has shot through the roof, and the number of papers using those organisms has risen in recent years, the work has become up to five times less efficient -- meaning, the same amount of funding produces fewer papers than it did before. "The price of the research was multiplied by maybe a factor of 5 for anthrax and maybe a factor of 2 for Ebola," said Carnegie Mellon University associate professor linkurl:Elizabeth Casman,;http://www.epp.cmu.edu/people/bios/casman.html who led an linkurl:analysis;http://www.pnas.org/cgi/doi/10.1073/pnas.0915002107 of the select agent literature that is published in this week's issue of the __Proceedings of the National Academy of Sciences__. Casman told __The Scientist__ that her group found, for example, that prior to 2002, an average of 17 papers on anthrax were published for every $1 million of funding, whereas after 2002, that average dropped to 3. At issue, according to the analysis, are two laws designed to regulate select agent research: the linkurl:PATRIOT Act;http://epic.org/privacy/terrorism/hr3162.html and the linkurl:Public Health Security and Bioterrorism Preparedness and Response Act,;http://thomas.loc.gov/cgi-bin/query/z?c107:H.R.3448.ENR: enacted in 2001 and 2002, respectively. The laws' new regulations govern the exhaustive documentation of the transportation, guarding, and use of select agents. As a result, they are burying researchers studying select agents with administrative duties, Casman noted. Researchers to whom Casman spoke "all complained of the paperwork," she said. "A lot of it, they just find overwhelming." Some researchers told Casman that their work took twice as long to carry out because of all the paperwork related to select agents, and that money was being diverted from research expenses to pay for things like security cameras, hiring guards, and building walls. "It's expensive to comply with the regulations," Casman said. "It is getting grossly impossible to do meaningful research," linkurl:Martin Hugh-Jones,;http://www.vetmed.lsu.edu/pbs/hugh-jones.html Professor Emeritus at Louisiana State University and coordinator for the World Health Organization's Working Group on Anthrax Research and Control, told __The Scientist__. "The paperwork now is unbelievable," said Hugh-Jones, who Casman interviewed as part of the study. Casman and her team also found that US labs working on anthrax or Ebola are also collaborating less with labs outside of the US, likely a result of restrictions in the laws. "International collaborations between a US author and a non-US author were inhibited," she said. linkurl:Lisa Hensley,;http://cpol.army.mil/library/news/acp/0710cpom.html virologist and chief of the Viral Therapeutics and Virology Division at the US Army's Research Institute of Infectious Diseases in Maryland, agreed that it is much harder for her to work with foreign labs on projects involving Ebola or any of the other potentially weaponizable pathogens she studies. Also, Hensley told __The Scientist__ that other countries have adopted stringent laws around working with select agents that mirror the US laws and create a "hesitancy by international partners to share viral stock samples with us." For example, Hensley's lab has faced huge obstacles in obtaining a sample of a Crimean-Congo hemorrhagic fever virus that killed a US Army soldier in Afghanistan last year. Hensley said that the soldier was taken to a German research institute for further study after his death, but that samples of the virus have not yet made it to her lab. "We've been trying for nine months to get the isolate shipped to us," she said, adding that the US Army enforces further regulations beyond those codified in the PATRIOT Act and other federal laws. Hensley also noted that in 1998, when she first came to her Army lab, it took her about a month to get clearance to enter the BSL-4 facility, which is the highest security level lab, necessary to house and study Ebola virus. Now with all the background checks and psychological and medical testing required of laboratory workers, she said, "It easily takes close to 6-9 months from the time somebody walks into the door before they have access to a containment lab." And that's just to get into a BSL-3 lab to train to be in a BSL-4 lab. Casman said that the key to increasing the efficiency and reach of select agent research starts with reducing the amount of paperwork required of researchers. For instance, they must record precise volumes of samples and submit those values to authorities -- even when moving droppers of virus or bacteria from one container to another within a lab. "There are certain things that can be done to make the lives of the scientists easier," Casman said. "Making the paperwork less absurd would really help." Hensley, who was also interviewed by Casman as part of the study, said that she marshals on with her work, despite its administrative burden. "We accept all the regulations as the price of doing business, but it does slow down the timeline," she said. "It's just a much different world than it used to be."
**__Related stories:__***linkurl:Biosecurity rules under review;http://www.the-scientist.com/news/display/55821/
[9th July 2009]*linkurl:Security woes halt Army research;http://www.the-scientist.com/blog/display/55407/
[9th February 2009]*linkurl:How to fix biosecurity?;http://www.the-scientist.com/blog/display/55166/
[4th November 2008]

Biosecurity laws hobble research

The Scientist ARCHIVES

Become a Member of

Meet the Author

Bob Grant

Related Research Resources

What Is the Amniotic Fluid Composed of?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Maximizing Cancer Research Model Systems

Products

Product News

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas